Latest news with #CD20
Yahoo
04-07-2025
- Business
- Yahoo
ATOM Consolidates as Bitcoin Takes Driving Seat, Finds Support at $4.20
The altcoin market took a backseat on Thursday as crypto majors bitcoin and ether attempted to rally to new highs. As billions of dollars worth of liquidity flowed into shorting bitcoin on the brink of record highs, altcoins like ATOM consolidated, finding support at the $4.20 level. Typically when bitcoin rallies altcoin price action is muted and the inverse is true when bitcoin consolidates, so ATOM could be primed for a rally once bitcoin begins to cool off. Technical analysis ATOM-USD traded within a range of $4.09 to $4.26 during the 24-hour period from 2 July 16:00 to 3 July 15:00, representing a 4% swing. Key support established at $4.16-$4.17 with high volume buying emerging at the $4.20 level during the 13:00 hour session on July 3rd. Despite reaching a peak of $4.26 during the 07:00 hour, ATOM failed to sustain momentum above the $4.25 resistance level. In the last 60 minutes from 3 July 14:24 to 15:23, ATOM-USD declined from $4.24 to $4.21, representing a 0.73% decrease. Sharp selloff occurred between 15:03-15:07, dropping to a session low of $4.19, before staging a recovery. Final 15 minutes showed stabilization with price consolidation around $4.21, suggesting potential short-term equilibrium. CD20 Index Surges 2% Before Profit-Taking Emerges The CD20 demonstrated significant volatility in the last 24 hours from 2 July 16:00 to 3 July 15:00, reaching a peak of $1,811.11 before retracing to $1,793.55, with an overall range of $37.27 (2%). After establishing support around $1,780 during early hours, the index staged an impressive rally through the morning session of 3 July, gaining momentum particularly between 09:00-14:00 before profit-taking emerged in the final hour.
Yahoo
27-06-2025
- Business
- Yahoo
NEAR Tumbles 5% as Altcoin Market Fails to Sustain Rally
The cryptocurrency market is feeling the effects of broader uncertainty in equities as NEAR Protocol dropped 5.01% from $2.16 to $2.06 during the 24-hour period from June 25 to June 26. The bearish pressure culminated in a sharp sell-off between 13:36-13:51 on June 26, when NEAR plunged to a session low of $2.05 on heavy volume exceeding 154K tokens. Technical Analysis NEAR formed a clear bearish channel with resistance at $2.17-$2.19 and support at $2.09-$2.10, which was eventually broken on heavy volume exceeding 3.9M NEAR during the 12:00 hour. Notable volume spikes occurred during the 09:00-12:00 timeframe as selling pressure intensified, with the asset reaching its lowest point at $2.05 during the 13:00 hour. A potential double bottom pattern formed in the final 15 minutes of the analyzed period as buyers stepped in with increasing volume, suggesting possible short-term stabilization. The total price range over the 24-hour period was $0.14 (6.55%), indicating significant volatility. CoinDesk 20 Index Whipsaws as Early Gains Evaporate The CD20 demonstrated significant volatility over the last 24 hours from 25 June 15:00 to 26 June 14:00, with a price range of $22.40 (1.29%). After reaching a peak of $1,762.50, the index retreated to $1,740.10, as early bullish momentum gave way to consistent selling pressure throughout the morning session. This pattern erased nearly all gains and suggests potential further downside if support at $1,740 fails to hold.
Yahoo
09-06-2025
- Business
- Yahoo
ATOM Struggles After Failed Breakout, Recovers With New Support at $4.237
ATOM ATOM, the token of the Cosmos ecosystem, experienced volatility over the past 24 hours, with the price ranging 2.76% and peaking at $4.327. Strong resistance emerged around that level, with high trading volume creating a rejection zone that prevented further advances, according to CoinDesk Research's technical analysis model. The Cosmos ecosystem, a network comprised of many independent blockchains, continues expanding its cross-chain capabilities through the Eureka upgrade, which kicked in April, enabling seamless communication with the Ethereum blockchain. Institutional developments including Bitbank's ATOM listing with promotional fee structures and Canary Capital's exploration of a Cosmos-backed ETF also provided support. Support established around $4.21, with price stabilizing near $4.233 during consolidation phase. Significant hourly recovery occurred between 07:33-08:02, with price surging to $4.239 on heavy volume exceeding 16,000 units. New support level formed at $4.237 following the 1.4% bounce from the hour's low. The CD20 demonstrated notable volatility over the 24-hour period, reaching a peak of 1751.049 before falling back, with an overall range of 22.573 points (1.3%). After establishing a 24-hour high during the 22:00 hour on June 8th, CD20 entered a consolidation phase, retracing approximately 50% of its gains while maintaining support above the 1730 level, suggesting potential stabilization following the recent upward momentum. Disclaimer: Parts of this article were generated with the assistance from AI tools and reviewed by our editorial team to ensure accuracy and adherence to our standards. For more information, see CoinDesk's full AI Policy. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
15-05-2025
- Business
- Business Wire
Innate Pharma Highlights ANKET ® Abstracts Selected for the EHA 2025 Congress
MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (' Innate ' or the ' Company ') today announced that an abstract regarding IPH6501, its ANKET ® targeting CD20 B cells currently developed in relapsed and/or refractory Non-Hodgkin Lymphoma, has been selected for the European Hematology Association (EHA) Congress 2025, taking place June 12-15 in Milan, Italy. Abstract details Antitumor characterization of IPH6501, a novel il2v-armed tetraspecific NK cell engager targeting CD20 B cells, in DLBCL and FL patient samples, and in preclinical combination with R-CHOP Abstract Code: PS2004 Session: Poster session 2 Session Date/Time: Saturday, June 14, 2025, 18:30 – 19:30 CEST More information can be found on the EHA website. In addition, an abstract related to SAR'514/IPH6401 (developed by Sanofi) was accepted for online publication. Abstract Code: PB2850 About ANKET ® ANKET ® (A ntibody-based NK cell E ngager T herapeutics) is Innate's proprietary platform for developing next-generation, multi-specific natural killer (NK) cell engagers to treat certain types of cancer. This versatile, fit-for-purpose technology is creating an entirely new class of molecules to induce synthetic immunity against cancer. About IPH6501 IPH6501 is the first Antibody-based NK cell Engager Therapeutic to co-engage activating receptors on NK cells (NKp46 and CD16), IL-2R (but not the alpha subunit) through a variant of human IL-2, and a tumor antigen (CD20) via a single molecule, hence providing proliferation and activation signals targeted to NK cells and promoting their cytotoxic activity against CD20 expressing malignant cells. IPH6501 has shown better anti-tumor efficacy than approved benchmark antibodies in preclinical tumor models (Demaria, EHA 2023, Carrette, SITC 2024, Demaria et al, Science Immunology 2024). IPH6501 is currently being evaluated in a Phase 1/2 multicenter trial (NCT06088654), investigating the safety and tolerability of IPH6501 in patients with relapsed and/or refractory CD20-expressing B-cell Non-Hodgkin's Lymphoma. About Innate Pharma Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET ® (Antibody-based NK cell Engager Therapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs). Innate's portfolio includes several ANKET ® drug candidates to address multiple tumor types as well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer. Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients. Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. Learn more about Innate Pharma at Follow us on LinkedIn and X. Information about Innate Pharma shares Disclaimer on forward-looking information and risk factors This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including 'anticipate,' 'believe,' 'can,' 'could,' 'estimate,' 'expect,' 'may,' 'might,' 'potential,' 'intend,' 'should,' 'will,' or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company's reliance on third parties to manufacture its product candidates, the Company's commercialization efforts and the Company's continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ('Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority ('AMF'), which is available on the AMF website or on Innate Pharma's website, and public filings and reports filed with the U.S. Securities and Exchange Commission ('SEC'), including the Company's Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company's website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
Yahoo
15-05-2025
- Business
- Yahoo
Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress
MARSEILLE, France, May 15, 2025--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that an abstract regarding IPH6501, its ANKET® targeting CD20 B cells currently developed in relapsed and/or refractory Non-Hodgkin Lymphoma, has been selected for the European Hematology Association (EHA) Congress 2025, taking place June 12-15 in Milan, Italy. Abstract details Antitumor characterization of IPH6501, a novel il2v-armed tetraspecific NK cell engager targeting CD20 B cells, in DLBCL and FL patient samples, and in preclinical combination with R-CHOP Abstract Code: PS2004Session: Poster session 2Session Date/Time: Saturday, June 14, 2025, 18:30 – 19:30 CESTMore information can be found on the EHA website. In addition, an abstract related to SAR'514/IPH6401 (developed by Sanofi) was accepted for online publication. The BCMA NK Cell Engager SAR'514 Induces Macrophage-Mediated Phagocytosis which is improved by combination with Evorpacept, a CD47 Blocker, in Multiple Myeloma Abstract Code: PB2850 About ANKET® ANKET® (Antibody-based NK cell Engager Therapeutics) is Innate's proprietary platform for developing next-generation, multi-specific natural killer (NK) cell engagers to treat certain types of cancer. This versatile, fit-for-purpose technology is creating an entirely new class of molecules to induce synthetic immunity against cancer. About IPH6501 IPH6501 is the first Antibody-based NK cell Engager Therapeutic to co-engage activating receptors on NK cells (NKp46 and CD16), IL-2R (but not the alpha subunit) through a variant of human IL-2, and a tumor antigen (CD20) via a single molecule, hence providing proliferation and activation signals targeted to NK cells and promoting their cytotoxic activity against CD20 expressing malignant cells. IPH6501 has shown better anti-tumor efficacy than approved benchmark antibodies in preclinical tumor models (Demaria, EHA 2023, Carrette, SITC 2024, Demaria et al, Science Immunology 2024). IPH6501 is currently being evaluated in a Phase 1/2 multicenter trial (NCT06088654), investigating the safety and tolerability of IPH6501 in patients with relapsed and/or refractory CD20-expressing B-cell Non-Hodgkin's Lymphoma. About Innate Pharma Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET® (Antibody-based NK cell Engager Therapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs). Innate's portfolio includes several ANKET® drug candidates to address multiple tumor types as well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer. Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients. Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. Learn more about Innate Pharma at Follow us on LinkedIn and X. Information about Innate Pharma shares ISIN code Ticker code LEI FR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29 Disclaimer on forward-looking information and risk factors This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including "anticipate," "believe," "can," "could," "estimate," "expect," "may," "might," "potential," "intend," "should," "will," or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company's reliance on third parties to manufacture its product candidates, the Company's commercialization efforts and the Company's continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority ("AMF"), which is available on the AMF website or on Innate Pharma's website, and public filings and reports filed with the U.S. Securities and Exchange Commission ("SEC"), including the Company's Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company's website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country. View source version on Contacts For additional information, please contact: Investors Innate Pharma Henry WheelerTel.: +33 (0)4 84 90 32 Media Relations NewCap Arthur RouilléTel.: +33 (0)1 44 71 00 15innate@
